Taiko Pharmaceutical Co.,Ltd. (4574.T)

JPY 322.0

(0.0%)

Market Cap (In JPY)

16.16 Billion

Revenue (In JPY)

5.04 Billion

Net Income (In JPY)

-4.89 Billion

Avg. Volume

224.95 Thousand

Currency
JPY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
263.0-495.0
PE
-
EPS
-
Beta Value
0.108
ISIN
JP3442200006
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Takashi Shibata
Employee Count
-
Website
https://www.seirogan.co.jp
Ipo Date
2009-03-18
Details
Taiko Pharmaceutical Co.,Ltd. engages in pharmaceuticals, infection control, and other businesses. The company manufactures and sells non-prescription drugs under the Seirogan and Seirogan Toi-A brands for the treatment of loose stools, diarrhea, food and water poisoning, vomiting, and related conditions; tablets for diarrhea; and quasi-drugs, such as Trumpet Intestinal Regulator BF. It also manufactures and sells sanitation control products under the Cleverin brand name to wholesalers, as well as Cleverin generator, a machine that emits low concentrations of chlorine dioxide gas; and supplies products using the patented Cleverin technology through OEM agreements and products developed jointly with other companies. It exports its products to the United States, Canada, Thailand, Vietnam, Malaysia, and Mongolia. Taiko Pharmaceutical Co.,Ltd. was incorporated in 1946 and is headquartered in Osaka, Japan.`